Anthony Polverino has been appointed executive vice president of early development and chief scientific officer of Vancouver, BC-based Zymeworks (NYSE: ZYME). Polverino most recently worked at Kite Pharma, where he was interim chief scientific officer, and prior to that, vice president of research. Kite was acquired by Gilead Sciences (NASDAQ: GILD) last year. Zymeworks develops cancer treatments called bispecific antibodies. The company is currently testing its lead drug, ZW25, in a Phase 1 study as a potential treatment for breast cancer.